Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122742 | 1.00 | HIF1A (0.46) | HIF1ASMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL4110227 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRALDH1A1LMNAMEN1 | |
| SCHEMBL4110223 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRALDH1A1LMNAMEN1 | |
| SCHEMBL4122272 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRALDH1A1LMNAMEN1 | |
| SCHEMBL27494874 | 0.85 | HIF1A (0.46) | HIF1ASMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL4117318 | 0.82 | SMN1; SMN2 (0.42) | HIF1ASMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL4117315 | 0.82 | SMN1; SMN2 (0.42) | HIF1ASMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL7773929 | 0.82 | HIF1A (0.47) | HIF1ASMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL8613983 | 0.82 | HIF1A (0.53) | HIF1ASMN1; SMN2TSHRALDH1A1LMNA | |
| SCHEMBL3625146 | 0.82 | HIF1A (0.47) | HIF1ASMN1; SMN2TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258302-B2 | Method for producing benzazepinone | API CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1985615-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | NISCH, GABBR1, GABBR2 | HIF1A 4026/4885SMN1; SMN2 3973/4885TSHR 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.